Patients struggle with lack of consistent coverage for popular weight-loss drugs
Supplies of high-demand obesity treatments are improving, but that doesn’t mean it’s easier to get them. Many employers and insurers are scaling back coverage of Wegovy and Zepbound and a key government program, Medicare, doesn’t cover the drugs for obesity. Meanwhile, some big employers are adding coverage, but their commitment isn’t guaranteed. Treatment prices that can top hundreds of dollars monthly even after discounts make it hard for many people to afford these drugs on their own. That can make the life-changing weight loss that patients seek dependent on the coverage ...